

# SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling

Zuzana Koledova<sup>a,b,c,d</sup>, Xiaohong Zhang<sup>a,b</sup>, Charles Streuli<sup>a,b</sup>, Robert B. Clarke<sup>e</sup>, Ophir D. Klein<sup>f,g,h,i</sup>, Zena Werb<sup>j,1</sup>, and Pengfei Lu<sup>d,1</sup>

<sup>a</sup>Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom; <sup>b</sup>Wellcome Trust Centre for Cell Matrix Research, University of Manchester, Manchester M13 9PT, United Kingdom; <sup>c</sup>Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic; <sup>d</sup>School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; <sup>e</sup>Breast Cancer Now Research Unit, Institute of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, United Kingdom; <sup>f</sup>Department of Orofacial Sciences, University of California, San Francisco, CA 94143; <sup>g</sup>Department of Pediatrics, University of California, San Francisco, CA 94143; <sup>h</sup>Program in Craniofacial Biology, University of California, San Francisco, CA 94143; <sup>i</sup>Institute for Human Genetics, University of California, San Francisco, CA 94143; and <sup>j</sup>Department of Anatomy, University of California, San Francisco, CA 94143

Contributed by Zena Werb, July 17, 2016 (sent for review December 24, 2014; reviewed by Cathrin Brisken and Jeffrey Rosen)

**The role of the local microenvironment in influencing cell behavior is central to both normal development and cancer formation. Here, we show that sprouty 1 (SPRY1) modulates the microenvironment to enable proper mammary branching morphogenesis. This process occurs through negative regulation of epidermal growth factor receptor (EGFR) signaling in mammary stroma. Loss of SPRY1 resulted in up-regulation of EGFR–extracellular signal–regulated kinase (ERK) signaling in response to amphiregulin and transforming growth factor alpha stimulation. Consequently, stromal paracrine signaling and ECM remodeling is augmented, leading to increased epithelial branching in the mutant gland. By contrast, down-regulation of EGFR–ERK signaling due to gain of Sprouty function in the stroma led to stunted epithelial branching. Taken together, our results show that modulation of stromal paracrine signaling and ECM remodeling by SPRY1 regulates mammary epithelial morphogenesis during postnatal development.**

branching morphogenesis | FGF signaling | EGF signaling | epithelial–stromal interactions | stromal microenvironment

A central theme in developmental and cancer biology research is to understand the mechanisms by which the local microenvironment, or niche, influences fundamental aspects of cell and tissue behavior during organ formation and function (1). The importance of mesenchyme, as the embryonic niche, in determining organ identity and fate of the epithelium was demonstrated long ago by classic embryological studies (2, 3). More recent studies have shown, however, that postnatal stroma, a derivative of embryonic mesenchyme, is essential for maintenance of cell fate and differentiation status in adult life (4, 5). Indeed, abnormal stroma can lead to the formation of a cancer microenvironment, and it plays a causative role during tumor onset and progression (1, 6). As such, understanding postnatal stromal biology and the mechanism by which its deregulation may promote tumorigenesis is of key importance.

The mouse mammary gland is a powerful model for understanding the genetic and cellular basis of stromal biology (7). The observation that epithelial branching of the mammary gland persists for many weeks after birth has made amenable the detection of stromal influences on epithelial invasion and patterning (8, 9). Indeed, postnatal mammary stroma is composed of many cell types, including periductal fibroblasts and white adipocytes, endothelial cells, nerve cells, and a variety of infiltrating immune cells, including macrophages and eosinophils, which play an important role in postnatal branching (10).

Mammary stroma regulates epithelial branching by at least two mechanisms. Stromal cells produce several paracrine factors, including fibroblast growth factors (FGFs) and insulin-like growth factor (IGF) that activate receptor tyrosine kinases (RTK) (11, 12). For

example, a reduction in FGF signaling due to loss of FGF10 or its receptor FGF receptor 1/2 (FGFR1/2), or reduced IGF signaling, leads to stunted epithelial branching (13–16). By contrast, excessive FGF signaling due to overactive FGF ligand or receptor causes breast tumorigenesis in mouse models (17–19). In addition, stromal cells also play a major role in remodeling of the ECM, whose unique physical, biochemical, and biomechanical properties make it an essential component for a wide variety of developmental processes including epithelial branching (1, 6). ECM remodeling is highly regulated and its deregulation is a major contributor to tumorigenesis (20).

The postnatal mammary gland stroma is under both systemic hormonal and local control based on epithelial-derived paracrine signaling via, for example, the EGF receptor (EGFR) pathway (21). Whereas a reduction in stromal EGFR signaling due to genetic ablation of the receptor or its ligands, including amphiregulin (AREG) and transforming growth factor alpha (TGF $\alpha$ ), leads to deficient epithelial branching (22–24), excessive EGFR signaling causes breast tumorigenesis and is a therapeutic target of human cancer (25, 26). Thus, stromal EGFR signaling is important for epithelial branching of the mammary gland.

## Significance

Despite its importance in epithelial development and in breast cancer, the role of EGF receptor (EGFR) signaling and its regulation in the postnatal mammary stroma has remained unclear. Here, we show that sprouty 1 (*Spry1*) modulates epithelial–stromal interactions by inhibiting EGFR-dependent stromal paracrine signaling and ECM remodeling. *Spry1* loss leads to upregulated EGFR signaling and enhanced stromal activities, including ECM remodeling and growth factor production, and ultimately increased epithelial branching. By contrast, EGFR signaling reduction in fibroblasts leads to stunted epithelial branching. We show that EGFR and FGF receptor (FGFR) signaling constitute a critical part of stromal–epithelial interactions during postnatal development and that these signaling pathways are fine-tuned by different members of the *Sprouty* gene family to ensure normal epithelial morphogenesis of the mammary gland.

Author contributions: Z.K., Z.W., and P.L. designed research; Z.K., X.Z., and P.L. performed research; C.S., R.B.C., O.D.K., and Z.W. contributed new reagents/analytic tools; Z.K., X.Z., C.S., R.B.C., O.D.K., Z.W., and P.L. analyzed data; and Z.K., Z.W., and P.L. wrote the paper.

Reviewers: C.B., Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne; and J.R., Baylor College of Medicine.

The authors declare no conflict of interest.

<sup>1</sup>To whom correspondence may be addressed. Email: lvpf@shanghaitech.edu.cn or zena.werb@ucsf.edu.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1611532113/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1611532113/-DCSupplemental).


Despite its requirement for epithelial branching, the mechanisms by which EGFR signaling functions and is modulated in the mammary gland stroma have remained unclear. Here, we hypothesized that members of the Sprouty family, which encode intracellular RTK signaling inhibitors essential for numerous vertebrate developmental processes (27–30), regulate EGFR signaling in the mammary gland stroma. To test this hypothesis, we determined the mammary gland phenotype in mice lacking sprouty 1 (*Spry1*) and analyzed the mechanisms by which SPRY1 functions. These studies revealed an important role for SPRY1 in mammary gland stromal–epithelial cross talk.

## Results

***Spry1* Is Expressed in Mammary Stroma and Basal Epithelium.** We examined the expression of *Spry1* during various stages of postnatal mammary gland development. *Spry1* mRNA was readily detected

at all of the stages examined by quantitative real-time PCR (qPCR), including during epithelial branching, pregnancy, lactation, and involution (Fig. 1A). We used fluorescence-activated cell sorting (FACS) to sort mammary epithelia based on their expression of CD24 and CD49f cell surface markers (Fig. 1B). *Spry1* was highly expressed in basal (CD24<sup>med</sup>CD49f<sup>hi</sup>) and stromal (CD24<sup>neg</sup>CD49f<sup>neg</sup>) cells compared with low levels in luminal cells (CD24<sup>hi</sup>CD49f<sup>low</sup>) (Fig. 1C).

To assess the spatiotemporal patterns of *Spry1* expression during mammary gland development, we took advantage of *Spry1*<sup>LacZ/+</sup> (*Spry1* heterozygous, *Spry1*<sup>het</sup>) mice carrying the *Spry1*<sup>LacZ</sup> allele, which is a null allele that also reports *Spry1* expression due to replacement of essential functional domains by the *LacZ* gene (31). *Spry1* was expressed in many tissues of the developing embryo at embryonic day 12.5 (E12.5) (Fig. 1D and D'), including both the mammary bud epithelium and mesenchyme (Fig. 1E). In pubertal mammary glands, when epithelial



**Fig. 1.** Epithelial branching is increased in mammary glands lacking *Spry1* function. (A–C) *Spry1* expression in mammary gland. (A) Relative *Spry1* expression during mammary gland development as detected by qPCR and normalized to *Actb*. RNA was isolated from mammary glands from virgin female mice at 3, 5, and 10 wk of age, and female mice on day 5 of pregnancy (Preg), day 1 of lactation (Lac), and days 1, 3, and 10 of involution (Inv). Graph shows mean  $\pm$  SD ( $n = 3$ ). Statistical analysis was performed using one-way ANOVA; \*\*\*\* $P < 0.0001$ . (B) Gating strategy for sorting of mammary gland cell populations by FACS; basal (ba), luminal (lu), and stromal (st) cells. (C) Relative expression of *Spry1* in sorted luminal, basal, and stromal cells, normalized to *Actb*. (D–H) *Spry1* expression during embryonic (D and E) and postnatal mammary gland development (F–H) as detected by  $\beta$ -galactosidase ( $\beta$ -gal) staining on *Spry1*<sup>het</sup> embryos or tissues. (D and D') *Spry1* expression in mammary bud (MB) #2, #3, and #4 (arrowheads) at E12.5. (E) Cross-section of the MB; ME, mammary epithelium; MM, mammary mesenchyme. Nuclei were counterstained with nuclear fast red. (Scale bar, 50  $\mu$ m.) (F–H) *Spry1* expression in the whole-mount (F) and paraffin sections (G and H) of mammary gland at 5 wk of age as detected by  $\beta$ -gal staining. (F) *Spry1* is expressed in the branching epithelial network as well as in the blood vessels (bv; arrows). (Scale bars, 5 mm.) (G, H) Cross sections of  $\beta$ -gal-stained mammary duct (G) and terminal end bud (TEB) (H) revealed expression of *Spry1* in fibroblasts (fi), basal cells (ba), and caps cells (ca). Nuclei were counterstained with nuclear fast red. (Scale bars, 100  $\mu$ m.) (I) Whole mounts of mammary glands from 5-, 8-, and 12-wk-old *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> mice stained with carmine red. Images of parts of the mammary gland were merged in Photoshop (Adobe) to create a full view of the wholemount gland. Arrows indicate the extent of ductal penetration in the fat pad; dotted white line illustrates the epithelial invasion front. (Scale bars, 5 mm.) (J–L) Quantitative comparisons of ductal penetration (J), number of TEBS (K), and branching (L) between *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> glands. Plots show mean  $\pm$  SD ( $n = 3$ –6 litters/age). Statistical analysis was performed using two-way ANOVA; \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\*\* $P < 0.001$ .

branching is ongoing, we detected *Spry1* expression in the branching epithelial network and blood vessels in the distal stroma (Fig. 1F). Histological sections of stained mammary glands confirmed that *Spry1* is expressed in periductal fibroblasts (Fig. 1G and H), cap cells of terminal end buds (Fig. 1H), and the basal ductal epithelium (Fig. 1G), but there was little expression in the luminal epithelium.

**Loss of *Spry1* Function Leads to Increased Branching Activities in the Mammary Epithelium.** We examined whether the mammary gland develops normally in mice lacking *Spry1* function. Compared with mammary glands from pubertal and adult virgin *Spry1*<sup>+/+</sup> [*Spry1* wild-type (*Spry1*<sup>wt</sup>)] mice, those from *Spry1*<sup>LacZ/LacZ</sup> (*Spry1*<sup>het</sup>) mice did not show any significant differences in ductal penetration, terminal end buds (TEBs), or branching (Fig. S1 A–D). These findings were consistent with previously reported haploinsufficiency of *Sprouty* genes in various vertebrate developmental processes (27, 32, 33).

However, when we compared mammary glands from pubertal and adult virgin *Spry1*<sup>het</sup> and *Spry1*<sup>LacZ/LacZ</sup> [*Spry1* knockout (*Spry1*<sup>KO</sup>)] female mice, we found significant differences in epithelial morphogenesis. In mice at 8 and 12 wk of age, the epithelium of the KO animals reached further into the fat pad (Fig. 1I and J). Moreover, at 8 wk of age, mammary glands from *Spry1*<sup>KO</sup> mice showed increased number of TEBs (Fig. 1K) and increased branching (Fig. 1L).

Interestingly, this branching phenotype was resolved at 12 wk of age. The lack of overall major defects in *Spry1*<sup>KO</sup> mammary glands suggests that other family members could compensate for loss of *Spry1*. Indeed, *Spry2* (30) and *Spry4* were expressed in the mammary gland (Fig. S1 E–G), although *Spry3* was not detectable. The spatiotemporal pattern of *Spry4* expression was most similar to *Spry1*, suggesting that *Spry4* may be redundant for *Spry1*.

These results reveal that *Spry1* negatively regulates epithelial invasion and branching in pubertal mammary gland. However, our data suggest that the loss of *Spry1* can be overcome by other *Spry* proteins later in development.

***Spry1* Loss in the Mammary Epithelium Does Not Affect Mammary Branching.** Our observation that *Spry1* is expressed in both the epithelium and the stroma of the mammary gland indicated that the branching phenotype of *Spry1*<sup>KO</sup> mice could result from defects in either compartment. Considering its expression in the basal layer, which is rich in adult stem cells (34), we asked whether *Spry1* is essential for mammary stem cell biology and thus epithelial expansion during branching morphogenesis. We used the mammosphere assay (35), which measures progenitor/stem cell potential of mammary epithelial cells based on their ability to survive and form mammospheric colonies in suspension (primary mammosphere assay) and to self-renew (secondary mammosphere assay), with two commonly used growth factors, EGF and/or FGF2. We observed no statistically significant difference in mammosphere forming efficiency between *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> cells in all cases (Fig. 2A and B, and Fig. S2 A and B).

Similarly, using the acinar assay (36), which measures the ability of mammary epithelial progenitor/stem cells to form acinus-like colonies in 3D Matrigel, we observed no statistically significant difference between *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> basal cells in acinus-forming efficiency (Fig. S2 C and D). Together, these results suggest that *Spry1* loss in basal cells is unlikely to have a major effect on mammary stem cell biology and to be the cause of the branching phenotype observed in *Spry1*<sup>KO</sup> mice.

Another possibility is that *Spry1*-null epithelium undergoes branching more readily than normal during postpubertal development. To examine this possibility, we performed 3D in vitro culture studies in which mammary epithelium forms branches in response to growth factor treatment (30). Mammary epithelium did not branch in the absence of growth factors but was able to

form branched structures in the presence of FGF2 or FGF7 (Fig. S2E). We found no significant differences between *Spry1*<sup>het</sup> organoids and *Spry1*<sup>KO</sup> organoids in their responses to FGF2 or FGF7 in terms of proportion of branched organoids (Fig. 2C) or number of branches per organoid (Fig. S2F). These data suggest that *Spry1*-null epithelium is not defective and responds to branching signals similarly to control epithelium.

To test whether loss of epithelial *Spry1* affects mammary branching in vivo, we transplanted 10,000 mammary epithelial cells (MECs) from *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> mice into “cleared” fat pads lacking the endogenous epithelial network of the #4 mammary gland in 3-wk-old nude mice (Fig. S2G). Five weeks after surgery, we harvested transplants and stained them with carmine red. We found that MECs derived from both *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> mice formed epithelial networks, but no significant difference was detected in epithelial branching (Fig. 2D and E).

These results show that the loss of *Spry1* in the epithelium does not affect mammary gland branching and is unlikely to be the cause of accelerated branching in *Spry1*<sup>KO</sup> mice.


**Loss of *Spry1* in Stromal Cells Promotes Increased Epithelial Branching in Vitro.** To determine whether *Spry1*-null stroma promotes increased epithelial branching, we developed an in vitro assay in which wild-type organoids were cocultured with fibroblasts harvested from *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> mice. Mammary organoids did not form branched structures when cultured in basal medium alone (Fig. 2F). However, when they were cocultured with fibroblasts, mammary organoids formed branches in 4–5 d (Fig. 2F), with more branches forming when more fibroblasts and organoids were present.

When cocultured with *Spry1*<sup>KO</sup> fibroblasts, the organoids branched more readily and formed more branches than with *Spry1*<sup>het</sup> fibroblasts (Fig. 2G and H). This observation is consistent with the in vivo phenotype and suggests that *Spry1*-null stroma promotes epithelial branching more strongly than controls.

These results indicate that the ductal phenotype arising from the loss of *Spry1* arises from defects within the stroma, rather than within the epithelium.

**In Mammary Fibroblasts, *Spry1* Is a Negative Regulator of EGFR-ERK Signaling in Response to AREG and TGF $\alpha$ .** *Sprouty* genes regulate RTK signaling in various developmental contexts (37, 38). Therefore, we used Western blotting to examine the phosphorylation and activation status of protein kinase B (AKT) and extracellular signal-regulated kinase (ERK), key components of the two main branches downstream of RTK signaling. We found that AKT activation (phospho-Ser473) was the same in *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> fibroblasts (Fig. 2I and J). In contrast, ERK phosphorylation at Thr202/Tyr204 was up-regulated in *Spry1*<sup>KO</sup> fibroblasts compared with *Spry1*<sup>het</sup> fibroblasts (Fig. 2I and K). These data indicate that *Spry1* loss leads to up-regulation of RTK signaling through the ERK arm of the pathway in mammary fibroblasts.

Next, we set out to determine whether *Spry1* regulates signaling via EGFR, an RTK that mediates epithelium-to-stroma communication during mammary branching (24). Interestingly, we found increased expression of candidate EGFR-responsive genes *Egr1* and *Fos* (39, 40) in *Spry1*<sup>KO</sup> fibroblasts (Fig. S3A). Moreover, treatment of *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> fibroblasts with EGFR ligands, including AREG (Fig. 2L and M) and TGF $\alpha$  (Fig. 2N and O), led to an increase of the strength and duration of ERK activation in *Spry1*<sup>KO</sup> fibroblasts compared with *Spry1*<sup>het</sup> fibroblasts. By contrast, we observed no significant difference in AKT activation between *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> fibroblasts in response to these two growth factors (Fig. S3 B–E). Furthermore, expression of both *Egr1* and *Fos* was up-regulated more strongly in *Spry1*<sup>KO</sup> fibroblasts than in *Spry1*<sup>het</sup> fibroblasts in response to AREG or TGF $\alpha$  treatment (Fig. S3F), suggesting



**Fig. 2.** *Spry1*-null fibroblasts are sensitized to AREG/TGF $\alpha$ -ERK signaling and show elevated activities in promoting epithelial branching in vitro. (A and B) Plots depicting primary (A) and secondary (B) mammosphere-forming efficiency (MFE) of *Spry1het* and *Spry1KO* basal cells. Data points show paired values, and lines indicate mean ( $n = 4$  or  $9$ ). Statistical analysis was performed using paired  $t$  test and revealed no significant difference in MFE between *Spry1het* and *Spry1KO* basal cells. (C) In vitro branching assay. *Spry1het* and *Spry1KO* organoids were cultured in Matrigel in basal organoid medium without any growth factor or supplemented with FGF2 or FGF7. Graphs show frequencies of formation of cysts and branched organoids, presented as mean  $\pm$  SEM ( $n = 4$ ). Statistical analysis was performed using paired  $t$  test and revealed no significant difference in organoid morphogenesis between *Spry1het* and *Spry1KO* basal cells. (D and E) Transplantation of *Spry1het* and *Spry1KO* MECs into wild-type fat pads. (D) Representative photographs of whole mounts harvested 5 wk after transplantation and stained with carmine red. (Scale bars, 2.5 mm.) (E) Quantification of epithelial branching. The plot shows mean  $\pm$  SEM ( $n = 7$  per genotype). Statistical analysis was performed using paired  $t$  test and revealed no significant difference in epithelial outgrowths between *Spry1het* and *Spry1KO* basal cells. (F-H) In vitro coculture branching assay, in which *Spry1het* or *Spry1KO* fibroblasts were cocultured with wild-type organoids [at the ratio of 100 or 1,000 fibroblasts (F) per organoid] in Matrigel in basal organoid medium without addition of growth factors. (F) Representative photographs of organoids in cocultures. (G) The graph shows frequencies of formation of cysts and branched organoids, presented as mean  $\pm$  SEM ( $n = 4$ ). Statistical analysis was performed using paired  $t$  test;  $*P < 0.05$ . (H) The graph shows number of branches per branched organoid, presented as mean  $\pm$  SD ( $n = 13-22$ ). Statistical analysis was performed using two-way ANOVA with multiple comparisons;  $****P < 0.0001$ ;  $***P < 0.001$ . (I-K) Western blot analysis of the phosphorylation status of AKT and ERK1/2 in *Spry1het* and *Spry1KO* fibroblasts cultured in normal medium with serum. (I) P-AKT (Ser473), AKT, P-ERK1/2 (Thr202/Tyr204), ERK, and  $\beta$ -actin signals were detected on a single blot. (J and K) Quantitative comparison of AKT (J) and ERK1/2 (K) phosphorylation. The plots show P-AKT (Ser473) band density, normalized to total AKT (J), and P-ERK1/2 (Thr202/Tyr204) band density, normalized to total ERK1/2 (K), as mean  $\pm$  SD ( $n = 3$ ). Statistical analysis was performed using paired  $t$  test;  $*P < 0.05$ . (L-O) Western blot analysis of phosphorylation status of ERK1/2 in *Spry1het* and *Spry1KO* fibroblasts in response to AREG (L and M) or TGF $\alpha$  stimulation (N and O). Fibroblasts were serum-starved, treated with 5 nM AREG or TGF $\alpha$  for the indicated time, and lysed, and on a single blot, P-ERK1/2 (Thr202/Tyr204), ERK, and  $\beta$ -actin signals were detected. (M and O) Quantitative comparison of ERK1/2 phosphorylation, normalized to total ERK1/2. Data are mean  $\pm$  SD ( $n = 3-5$ ). Statistical analysis was performed using two-way ANOVA;  $*P < 0.05$ ;  $**P < 0.01$ ;  $***P < 0.001$ .

that *Spry1KO* fibroblasts are sensitized to AREG/TGF $\alpha$ -EGFR-ERK signaling.

These results show that, when *Spry1* is deleted in mammary fibroblasts, there is increased EGFR signaling and more epithelial branching. Thus, fibroblast *Spry1* normally functions to negatively regulate AREG/TGF $\alpha$ -EGFR-ERK signaling.

**Mammary Stromal Fibroblasts Lacking *Spry1* Promote Epithelial Expansion and Migration in a Paracrine Fashion.** One mechanism by which *Spry1*-null fibroblasts might promote epithelial branching more strongly than normal is by increasing paracrine signaling to the epithelium. To examine this possibility, we developed an in vitro system in which aggregated fibroblasts, or “fibrospheres,” were cultured with organoids in close proximity (~100  $\mu$ m). When cultured alone in basal medium without growth factors, organoids and fibrospheres gradually shrank over the course of 2 d (Fig. S4). However, when cultured together, we observed mutual interactions between organoids and fibrospheres. Specifically, in the presence of *Spry1het* fibrospheres, a majority of organoids underwent cyst formation, and some of these organoids also migrated toward the fibrospheres (Fig. 3 A, E, and F, and Movie S1). Epithelial cyst formation and collective migration occurred at a higher frequency in the presence of *Spry1KO* fibrospheres (Fig. 3 A, E, and F and Movie S2). Under both experimental conditions, we observed extensions composed of fibroblasts protruding from fibrospheres, often in the direction of organoid epithelium (Fig. 3A).

The ability of fibrospheres to promote epithelial cyst formation and collective migration was increased by addition of AREG into the coculture (Fig. 3 B, E, and F), whereas it was inhibited by the highly selective EGFR inhibitor BIBX1382 (41) (Fig. 3C). These results suggest that the ability of fibrospheres to promote cyst formation and migration is positively regulated by EGFR signaling. Moreover, fibrosphere-induced epithelial response was rapid and was evident within 24 h (Fig. 3A and Movies S1 and S2), unlike the assays in which organoids formed branches after several days. The results thus suggest that fibrosphere influence on the epithelium is based on paracrine growth factors.

FGF ligands play distinct roles in epithelial morphogenesis of the mammary gland and, when delivered locally on heparin beads rather than uniformly in the medium, can trigger cyst formation and/or collective migration similar to fibrospheres (42). Thus, likely candidates by which fibrospheres influence the epithelium are FGF ligands, which are major epithelial branching signals produced in the mammary gland stroma. Indeed, the addition of FGFR signaling inhibitor SU5402 at 20  $\mu$ M, the concentration at which it selectively inhibits FGFR but not insulin receptor or PDGFR (43), effectively abrogated fibrosphere-induced epithelial morphogenesis (Fig. 3 D-F), suggesting that fibroblast-derived signals are, at least in part, ligands of the FGF family. Accordingly, we hypothesized that, if FGFs are indeed responsible for the *Spry1* loss-of-function phenotype, then FGF production would be higher in *Spry1KO* fibroblasts than in *Spry1het* fibroblasts. To test this hypothesis, we examined mRNA expression of several *Fgfs* that are expressed in the mammary gland stroma (42). As predicted, some of these *Fgfs*, including *Fgf1*, *Fgf7*, *Fgf8*, *Fgf9*, and *Fgf10* were more highly expressed in *Spry1KO* fibroblasts than in *Spry1het* fibroblasts (Fig. 3G). Interestingly, *Igf1*, another growth factor that promotes mammary gland development (14), was also up-regulated at the mRNA level in *Spry1KO* fibroblasts (Fig. 3G).

These results reveal that stromal fibroblasts can promote epithelial branching by providing growth factors, particularly those of the FGF family. In the *Spry1KO* fibroblasts, paracrine production is higher than in *Spry1het* cells, leading to an increase in ductal branching.

**Loss of *Spry1* Increases Collagen Remodeling and Promotes Epithelial Invasion.** Another mechanism by which *Spry1KO* stromal fibroblasts might promote epithelial branching more strongly than normal is by modulating ECM remodeling, which is essential for

epithelial behavior, including invasion and branching morphogenesis (1, 20). To test this possibility, we used a collagen contraction assay, in which remodeling of collagen matrix leads to contraction, to compare the ECM remodeling abilities between *Spry1het* fibroblasts and *Spry1KO* fibroblasts (Fig. 4A). We found that *Spry1KO* fibroblasts contracted collagen matrix more strongly than *Spry1het* fibroblasts (Fig. 4 B and C). Moreover, treatment with the EGFR inhibitor BIBX1382 attenuated collagen contraction abilities of *Spry1het* and *Spry1KO* fibroblasts (Fig. 4 B and C), suggesting that EGFR signaling regulates collagen remodeling in mammary fibroblasts.

Using qPCR, we next examined expression of several ECM-remodeling genes, including matrix metalloproteinases (*Mmps*) and lysyl oxidases (*Lox*, *Lox3*) in stromal fibroblasts. Compared with *Spry1het* fibroblasts, we found that expression of *Mmp2*, *Mmp11*, *Mmp14*, *Lox*, and *Lox3* was up-regulated in *Spry1KO* fibroblasts (Fig. 4D). These data suggest that *Spry1*-null fibroblasts promote epithelial branching in part by up-regulating expression of ECM-remodeling enzymes.


We also examined collagen deposition during mammary development by staining sections with Picosirius red. The amount of organized collagen progressively increased with age (Fig. 4 E and F), and there was a higher amount of organized collagen in *Spry1KO* glands than in *Spry1het* glands (Fig. 4F). Thus, the ECM becomes altered in *Spry1KO* mice.

Next, we investigated whether increased collagen-remodeling activity of *Spry1KO* fibroblasts could promote epithelial cell invasion. To this end, we used an organotypic invasion assay in which fibroblast-mediated ECM remodeling activity, rather than paracrine signaling, is the primary factor affecting epithelial/cancer cell invasion (44). Because primary MECs do not invade in this experimental setting, we used a stable breast cancer cells line MCF7-*ras*, which invades depending on fibroblast-mediated ECM remodeling. We measured matrix invasion by the MCF7-*ras* cells, which had been seeded on top of a dense collagen/Matrigel matrix embedded with either *Spry1het* or *Spry1KO* fibroblasts, 8 d after the coculture (Fig. 4G). We found that MCF7-*ras* cells invaded significantly deeper into the matrix remodeled by *Spry1KO* fibroblasts than by *Spry1het* fibroblasts (Fig. 4 H and I and Fig. S4B), indicating that *Spry1KO* fibroblasts are more effective at promoting epithelial invasion.

These results indicate that *Spry1KO* fibroblasts contribute to epithelial branching more strongly than normal, by up-regulating ECM remodeling. This upregulation of matrix remodeling is in part due to an increased expression of ECM-remodeling enzymes.

**Reduction of Stromal EGFR Signaling Leads to Decreased Epithelial Branching in Vivo.** A prediction that follows from our finding that up-regulation of EGFR signaling due to *Spry1* loss in stromal fibroblasts causes accelerated epithelial branching, is that reduction of EGFR signaling, for example, by gain of *Spry1* function in the mammary stroma, will lead to stunted epithelial branching.

SPRY1 and SPRY2 are biochemically similar and play redundant roles in the same cellular context (33, 37, 45). We therefore exploited a mouse line carrying a conditional *Spry2* gain-of-function allele (*Spry2-GOF*) (30, 46). We first determined whether Cre-mediated recombination could activate *Spry2-GOF* and, if so, whether *Spry2-GOF* could reduce EGFR signaling in the mammary stroma. To this end, we exposed fibroblasts from control and *Spry2-GOF* mice to adenovirus (Ad)-Cre-GFP, resulting in a high proportion expressing GFP (Fig. 5A). We then examined the responses of Ad-Cre-GFP-infected control and *Spry2-GOF* fibroblasts to AREG and TGF $\alpha$  treatment by Western blot analysis. As expected, AKT activation was unaffected by *Spry2* gain of function (Fig. S5 A-D). By contrast, ERK activation in *Spry2-GOF* fibroblasts was reduced compared with control fibroblasts (Fig. 5 B-E). Thus, ectopic expression of



**Fig. 3.** Mammary fibroblasts lacking *Spry1* promote epithelial morphogenesis more strongly than normal in a paracrine fashion. (A–D) Time course of in vitro cocultures of wild-type epithelium (Ep; Left) with *Spry1*<sup>het</sup> or *Spry1*<sup>KO</sup> fibrospheres (Fi; Right) in the absence (A) or presence (B) of AREG stimulation, EGFR inhibitor BIBX1382 (C), or FGFR inhibitor SU5402 (D). (A) The epithelium formed a cyst (hollow arrowhead) and underwent directional collective migration toward fibrospheres, whereas fibrospheres formed spiky extensions made of fibroblasts (filled arrowheads), often in the direction of the epithelium. The images were recorded using time-lapse microscopy over 48 h, and the respective movies can be seen in [Movies S1](#) and [S2](#). (B–D) The ability of the epithelium to undergo cyst formation and collective migration was increased by AREG addition (B) and inhibited by EGFR inhibitor BIBX1382 (C) or FGFR inhibitor SU5402 (D). (Scale bars, 200  $\mu$ m.) White dotted line indicates the original position of organoids at time 0 h. (E and F) Quantification of epithelial response to *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> fibrospheres. Plots show proportions, as well as actual numbers of organoids, that underwent cyst formation (E) or migration (F) out of total number of organoids per condition. (G) Relative expression of candidate growth factor genes in serum-starved *Spry1*<sup>het</sup> and *Spry1*<sup>KO</sup> fibroblasts, normalized to *Actb*. Data shown are mean  $\pm$  SEM ( $n = 3$ –4). Statistical analysis was performed using paired *t* test; \* $P < 0.05$ ; \*\* $P < 0.01$ . Refer to [Table S1](#) for primer sequences.


*Spry2* dampens AREG/TGF $\alpha$ -ERK signaling, validating the use of the *Spry2*-GOF mouse line to reduce EGFR signaling in stromal fibroblasts.

We crossed *Spry2*-GOF mice with *Fsp*-Cre mice [which have Cre activity in mammary fibroblasts (47)] to generate *Fsp*-Cre; *Spry2*-GOF female progeny, in which *Spry2*-GOF was activated in the mammary stroma (Fig. S5E) and there was down-regulated EGFR signaling (Fig. S5F). We found that, when the mammary glands of *Fsp*-Cre; *Spry2*-GOF mice were compared with those of controls at 5, 8, or 12 wk of age, ductal penetration and branch formation were reduced (Fig. 5 F–I).

These results confirm that reducing EGFR signaling in stromal fibroblasts leads to decreased epithelial branching in vivo.

## Discussion

In this study, we have gained insights into the nature of epithelial–stromal interactions in mammary gland development. We show that *Spry1* modulates epithelial–stromal interactions by negatively regulating EGFR-dependent stromal paracrine signaling and ECM remodeling (Fig. 5J). Loss of *Spry1* leads to up-regulated EGFR signaling and enhanced stromal activities, including ECM remodeling and growth factor production, which in turn leads to



**Fig. 4.** *Spry1KO* fibroblasts show increased ECM-remodeling activities and promote epithelial invasion more strongly than *Spry1het* fibroblasts. (A–C) Collagen contraction assay. (A) Diagram depicting the experimental procedure. (B) Photographs of a representative experiment. (C) Graph shows size change of collagen gels, expressed as percentage of the original area  $\pm$  SEM ( $n = 7$ ). Statistical analysis was performed using two-way ANOVA;  $*P < 0.05$ . (D) Expression of candidate ECM-modifying genes in *Spry1het* and *Spry1KO* fibroblasts cultured with serum, normalized to *Actb*. Values shown are the mean  $\pm$  SEM ( $n = 3$ ). Statistical analysis was performed using paired *t* test;  $*P < 0.05$ . Refer to Table S1 for primer sequences. (E and F) Collagen deposition in *Spry1het* and *Spry1KO* mammary glands during development as detected by picrosirius red staining on paraffin sections. (E) Bundles of organized collagen were visualized under polarized light; *insets* show images in bright field, which visualizes total collagen. (F) Quantification of organized collagen relative to the total amount of collagen. Values shown are the mean  $\pm$  SD ( $n = 9$ –16 per genotype). Statistical analysis was performed using two-way ANOVA;  $*P < 0.05$ ;  $****P < 0.0001$ . (Scale bars, 200  $\mu\text{m}$ .) (G–I) Organotypic invasion assays. (G) Diagram depicting the experimental procedure. (H) Representative images of hematoxylin- and eosin-stained cross-sections from the organotypic gels. Arrows show examples of MCF7-*ras* cell invasion depths. (Scale bars, 200  $\mu\text{m}$ .) (I) Quantification of organotypic invasion assay. The plots show pooled invasion depth or average maximum invasion depth of MCF7-*ras* cells per section. Values shown are the mean  $\pm$  SEM ( $n = 5$ ). Statistical analysis was performed using paired *t* test;  $*P < 0.05$ .


increased epithelial branching. By contrast, down-regulation of EGFR signaling in fibroblasts leads to stunted epithelial branching. Taken together with our findings of the significance of FGFR signaling within the epithelium (15, 16, 42), the results show that EGFR and FGFR signaling constitute a critical part of the molecular basis of stromal–epithelial interactions during postnatal development, and their modulation by *Sprouty* genes is essential for mammary gland formation and homeostasis.

***Spry1* Is Haplosufficient for Normal Mammary Gland Development.** In agreement with *Spry1* haplosufficiency in development of kidney, urinary tract, and external genitalia (27, 33), our study revealed that *Spry1* is haplosufficient during mammary development because we did not observe any difference in mammary branching between *Spry1wt* and *Spry1het* glands. The relatively minor phenotype of *Spry1KO* mammary glands suggests that loss of *Spry1* might be compensated by other stromal *Sprouty* genes. Indeed, we found that *Spry4* shows a similar expression pattern as *Spry1* in the developing mammary gland, suggesting that it may play a redundant function as *Spry1*. Future studies of other *Sprouty* genes in the mammary gland stroma, alone or in combination with *Spry1*,

should address this question regarding whether they play a similar or distinct role during mammary gland development.

It remains unclear why *Spry1* expression remains relatively stable throughout postpubertal development of the mammary gland but is greatly up-regulated at the 10-wk stage, when branching morphogenesis has all but finished in the adult female mice. One intriguing explanation for this observation is that, consistent with it being a negative regulator of mammary epithelial branching, *Spry1* may be up-regulated by an increased production of certain growth factor(s) to function as a critical component to halt the epithelial movement when the mammary tree has already been built and “unwanted”/dysregulated epithelial invasiveness beyond this point could harm the integrity and homeostasis of the functional mammary gland as in the case of breast cancer development.

**Stromal EGFR Signaling Promotes Epithelial Branching by Regulating ECM Remodeling.** Although it is well established that EGFR expression in the mammary gland stroma is required for epithelial branching, the mechanism by which EGFR signaling functions in the stroma has remained largely unclear. Our data show that



**Fig. 5.** Ectopic Sprouty expression dampens AREG/TGF $\alpha$ -ERK activation in stromal fibroblasts. (A) Photographs of control and *Spry2-GOF* fibroblasts transfected with Ad-Cre-GFP; *Left*, phase contrast (PC) images; *Right*, fluorescence (GFP) images. (Scale bars, 100  $\mu$ m.) (B–E) Western blot analysis of ERK1/2 phosphorylation status in control and *Spry2-GOF* fibroblasts in response to AREG (B and C) or TGF $\alpha$  stimulation (D and E). Fibroblasts were serum-starved, treated with 5 nM AREG or TGF $\alpha$  for the indicated durations, and lysed, and on a single blot, P-ERK1/2 (Thr202/Tyr204), ERK, and  $\beta$ -actin signals were detected. (C and E) Quantitative comparison of ERK1/2 phosphorylation, normalized to total ERK1/2, respectively. Data are mean  $\pm$  SD ( $n = 2/3$ ). Statistical analysis was performed using two-way ANOVA; \* $P < 0.05$ ; \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . (F–H) Carmine-stained whole-mount mammary glands from control and *Fsp-Cre;Spry2-GOF* mice at 5 and 8 wk of age. Arrows indicate the extent of ductal penetration in the fat pad; dotted lines indicate the epithelial invasion front. (G–I) Quantitative comparisons of ductal penetration (G), number of terminal end buds (TEBs) (H), and branching (I) between control and *Fsp-Cre;Spry2-GOF* glands. The plots show mean  $\pm$  SD ( $n = 3–12$  per genotype); \* $P < 0.05$ ; \*\* $P < 0.01$ . (Scale bars, 5 mm.) (J) Model diagram depicting the mechanism by which stromal EGFR signaling and epithelial FGFR signaling is regulated by *Sprouty* genes during mammary gland epithelial branching. Terminal end buds (TEBs) develop at the onset of puberty (3 wk after birth) at the distal tip of each primary duct, which invades the stroma in a proximal (pr)-to-distal (di) direction. Epithelial EGF ligands, including AREG and TGF $\alpha$ , activate EGFR signaling that is essential for FGF paracrine production and ECM remodeling. Levels of EGFR signaling are fine-tuned by stromal SPRY1 function so that an appropriate amount of FGFs and ECM-remodeling enzymes are produced during branching. By contrast, the interpretation of FGF activation by their receptors FGFR1/2 on the epithelium is modulated by SPRY2. As such, ductal elongation, collective migration, and other cell behavior essential for epithelial branching are orchestrated for the formation of the mammary gland.

stromal fibroblasts provide an essential component of the microenvironment for epithelial morphogenesis by promoting EGFR-dependent ECM remodeling via regulation of MMPs and other ECM remodeling enzymes including *Lox* genes. Our data showing up-regulation of *Mmp2*, *Mmp11*, *Mmp14*, *Lox*, and *Lox3* are consistent with a previous report on regulation of *Mmp* expression and collagen contraction by EGFR-ERK signaling in mouse embryonic fibroblasts (48). Importantly, several *Mmps*, including *Mmp2*, *Mmp3*, and *Mmp14*, have been shown to regulate mammary epithelial branching in vivo (49, 50).

Consistent with increased *Mmp* and *Lox* gene expression, we found that organized collagen deposition was higher in

*Spry1KO* mammary glands than in *Spry1het* glands during development. Although it remains unclear whether the increased deposition of organized collagen directly causes increased epithelial branching in *Spry1KO* mammary glands, emerging evidence now shows that stiffness of the ECM, including collagen, plays an important role in regulating epithelial behavior (reviewed in refs. 6, 20, and 51). Indeed, MCF7-*ras* cells invaded significantly deeper in the ECM that had been remodeled by *Spry1KO* fibroblasts than by *Spry1het* fibroblasts. These results thus suggest that epithelial branching, an important aspect of vertebrate epithelial branching, is increased in the absence of *Spry1*.

It is interesting that organized collagen deposition progressively increased with time during normal development. These results are consistent with an increase in collagen bundles and ECM stiffness in the stromal microenvironment in mouse tumor models (6). Taken together, the increased epithelial branching observed in *Spry1KO* mice is most likely a direct result of up-regulation of EGFR–ERK signaling in mutant stroma due to *Spry1* loss.

**EGFR and FGFR Signaling Pathways Underlie Stromal–Epithelial Interactions During Postnatal Mammary Gland Development.** In the presence of fibrospheres, mammary epithelium underwent rapid cyst formation and collective migration, suggesting that fibroblast influence is likely to be paracrine in nature. Interestingly, similar epithelial responses could be triggered by local delivery, as in the case of fibrospheres, of FGF ligands (42). The data thus point to FGFs as candidate mediators of the epithelial responses. Indeed, the addition of the FGFR inhibitor SU5402 abolished cyst formation and epithelial migration, suggesting that stroma-derived paracrine factors can, at least in part, be ascribed to ligands of the FGF family. This notion was confirmed by gene expression analysis based on qPCR, which showed that several stromal *Fgfs* were more strongly expressed in *Spry1KO* fibroblasts than in *Spry1het* fibroblasts.

Thus, the increased epithelial branching in *Spry1KO* gland is caused by overproduction of FGF ligands and possibly other paracrine factors, including IGF1, due to EGFR signaling up-regulation in the mutant stroma. This conclusion is consistent with the observation that increased epithelial branching can also directly result from FGF signaling up-regulation in the absence of its inhibitor SPRY2 in the epithelium (30). By contrast, EGFR signaling down-regulation due to gain of Sprouty function in the stromal fibroblasts led to retardation of epithelial branching. Indeed, epithelial branching is severely retarded or absent in the mammary stroma lacking *Egfr* function (24) or in the mammary epithelium lacking *Fgfr* (15, 16, 42).

Taken together, a reciprocal cross-talk mechanism exists in the developing mammary gland to regulate epithelial morphogenesis (Fig. 5J). On the one hand, epithelium-derived EGF family ligands, including AREG and TGF $\alpha$ , are essential for epithelial branching by targeting the mammary stroma. On the other hand, upon activation by AREG and TGF $\alpha$ , EGFR signaling promotes epithelial branching by a dual mechanism: indirectly by enhancing ECM remodeling and subsequently epithelial invasion, and directly by producing paracrine factors, including FGF ligands that target mammary epithelium via FGFR1 and FGFR2 signaling. Importantly, our data do not exclude the possibility that *Spry1* may regulate other RTKs, including IGFR, FGFR, or PDGFR in fibroblasts. Future studies will address whether these RTKs function in the mammary gland stroma and, if so, whether they are regulated by *Spry1*.

Reciprocal cross talk between epithelium and mesenchyme is a central theme in developmental biology, and this type of interaction is responsible for the specification, differentiation, and morphogenesis of many vertebrate organs during embryonic development (7). Our studies and others show that the mammary stroma, a derivative of embryonic mammary mesenchyme, engages in a similar cross talk with the epithelium during postnatal development, and perhaps in tissue homeostasis. A key aspect of future studies will be to understand how deregulation of stromal–epithelial cross talk may contribute to tumor onset and progression in the breast.

**A Model of Sprouty Gene Function in Epithelial Branching of the Mammary Gland.** Our working model is that SPRY1 suppresses overactive epithelial branching by inhibiting EGFR-dependent paracrine signaling and ECM remodeling in the mammary gland stroma (Fig. 5J). In the absence of SPRY1, epithelial branching is increased because paracrine signaling and ECM remodeling in the stromal microenvironment is augmented. By contrast, SPRY2 suppresses precocious epithelial branching by inhibiting FGFR signaling in the epithelium (30). In the absence of SPRY2, epithelial branching is increased because the epithelium is more sensitized to

FGF stimulation, and undergoes epithelial expansion, collective migration, and other essential aspects of epithelial branching more readily than normal.

It is interesting that different members of the *Sprouty* gene family are deployed in different tissues to modulate the reciprocal signaling between epithelium and stroma, thereby ensuring that overactive epithelial branching is prevented. Whether SPRY1 functions as an extrinsic “brake,” or SPRY2 acts as an intrinsic one in epithelial branching, they appear to perform the same function. The use of different Sprouty family members to fine-tune signaling between epithelium and mesenchyme reinforces the robustness of complex biological systems so that they can better withstand fluctuations of essential intrinsic or extrinsic factors during development and homeostasis.

## Materials and Methods

**Mouse Strains and Surgery.** Immunologically deficient female nude (*nu/nu*) mice were from Charles River Laboratories. CD-1 mice were obtained from institutional mouse colony (University of Manchester). Mice carrying the *Fsp-Cre* allele (47) were purchased from The Jackson Laboratory. Mice carrying the *Spry1<sup>LacZ</sup>* (31) allele and *Spry2-GOF* mice (46) were provided by M. Albert Basson, Department of Developmental and Stem Cell Biology, King's College of London, United Kingdom. Because *Sprouty* genes are haploinsufficient for various vertebrate developmental processes (27, 32, 33), we adopted a mating scheme wherein a *Spry1<sup>LacZ/LacZ</sup>* male mouse was crossed with a *Spry1<sup>LacZ/+</sup>* female mouse so that *Spry1het* control and *Spry1KO* mutant female mice were generated at a 1:1 ratio and this was in compliance with the United Kingdom's 3Rs policy. Mice were housed and maintained according to the Animal (Scientific Procedures) Act, 1986 (UK), project licence PPL 40/9865, and approved by the University of Manchester Ethical Review Process Committee and by ShanghaiTech University's Institutional Animal Care and Use Committee (IACUC# 2015SHT0006), and were genotyped according to methods in the publications describing establishment of the mouse lines.

**Isolation and Culture of Primary Mammary Organoids and Fibroblasts.** Primary mammary organoids were isolated and cultured as previously described (30). Briefly, mouse mammary glands were finely chopped, and mince was digested in collagenase buffer [with 0.2% collagenase (Sigma) and 0.2% trypsin (Life Technologies)]. Samples were centrifuged, washed several times, and treated with DNase I. Then they were subjected to five rounds of differential centrifugation (a short-pulse centrifugation at 450  $\times$  g), during which supernatant was collected and pellets were resuspended in DMEM/F12 (Invitrogen) for another round of differential centrifugation. The pellet containing mammary organoids was either plated in Matrigel (Corning) and overlaid with basal medium (DMEM/F12, 10  $\mu$ g/mL insulin, 5.5  $\mu$ g/mL transferrin, 6.7 ng/mL selenium, 100 U/mL penicillin, and 100  $\mu$ g/mL streptomycin), supplemented with 2.5 nM FGF2 or FGF7 if needed (for in vitro epithelial branching assay), or the organoids were further trypsinized to obtain a single-celled MEC solution (for FACS). Supernatant fractions were pooled and centrifuged, and pellets were resuspended in Fibroblast medium [DMEM (Invitrogen) with 10% (vol/vol) FBS (Sigma), 10  $\mu$ g/mL insulin, 5.5  $\mu$ g/mL transferrin, 6.7 ng/mL selenium, 100 U/mL penicillin, and 100  $\mu$ g/mL streptomycin] and seeded on a cell culture dish. After 30 min, when fibroblasts had already adhered to the dish whereas other cellular types remained in suspension, medium was aspirated and cell culture dish was washed twice with PBS and fresh Fibroblast medium was added. To prepare fibrospheres, fibroblasts were aggregated in low-adhesion plates overnight.

See *SI Materials and Methods* for additional details and more methods, including mammosphere and acinar assay, RNA isolation and qPCR (Table S1), mammary gland staining, in vitro epithelial branching and migration assays, Western blotting, collagen contraction and organotypic invasion assays, and statistical analyses.

**ACKNOWLEDGMENTS.** We thank Urszula Polanska for MCF7-*ras* cells and Xin Guo for performing fibrosphere assays. We thank Gary Freeman for critical reading of the manuscript. This work was supported by the project “Employment of Best Young Scientists for International Cooperation Empowerment” (CZ.1.07/2.3.00/30.0037), cofinanced by the European Social Fund and the state budget of the Czech Republic (GJ16-20031Y) (Czech Science Foundation); funds from the Faculty of Medicine, Masaryk University to junior research (to Z.K.); grants from Breast Cancer Now (to R.B.C. and P.L.); National Institutes of Health (NIH) Grant R03 HD060807 and a start-up grant from ShanghaiTech University (to P.L.); and NIH Grants R01 CA057621 (to Z.W.) and R01 DE021420 (to O.D.K.). The Wellcome Trust Center for Cell–Matrix Research, University of Manchester, is supported by core funding from the Wellcome Trust (088785/Z/09/Z).

1. Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: A dynamic niche in cancer progression. *J Cell Biol* 196(4):395–406.
2. Propper A, Gomot L (1973) Control of chick epidermis differentiation by rabbit mammary mesenchyme. *Experientia* 29(12):1543–1544.
3. Propper A, Gomot L (1967) [Tissue interactions during organogenesis of the mammary gland in the rabbit embryo.]. *C R Acad Sci Hebd Seances Acad Sci D* 264(22):2573–2575. French.
4. Booth BW, et al. (2008) The mammary microenvironment alters the differentiation repertoire of neural stem cells. *Proc Natl Acad Sci USA* 105(39):14891–14896.
5. Boulanger CA, Mack DL, Booth BW, Smith GH (2007) Interaction with the mammary microenvironment redirects spermatogenic cell fate in vivo. *Proc Natl Acad Sci USA* 104(10):3871–3876.
6. Egeblad M, Rasch MG, Weaver VM (2010) Dynamic interplay between the collagen scaffold and tumor evolution. *Curr Opin Cell Biol* 22(5):697–706.
7. Howard BA, Lu P (2014) Stromal regulation of embryonic and postnatal mammary epithelial development and differentiation. *Semin Cell Dev Biol* 25–26:43–51.
8. Watson CJ, Khaled WT (2008) Mammary development in the embryo and adult: A journey of morphogenesis and commitment. *Development* 135(6):995–1003.
9. Macias H, Hinck L (2012) Mammary gland development. *Wiley Interdiscip Rev Dev Biol* 1(4):533–557.
10. Lu P, Sternlicht MD, Werb Z (2006) Comparative mechanisms of branching morphogenesis in diverse systems. *J Mammary Gland Biol Neoplasia* 11(3–4):213–228.
11. Kim EJ, Jung HS, Lu P (2013) Pleiotropic functions of fibroblast growth factor signaling in embryonic mammary gland development. *J Mammary Gland Biol Neoplasia* 18(2):139–142.
12. Lu P, Werb Z (2008) Patterning mechanisms of branched organs. *Science* 322(5907):1506–1509.
13. Richards RG, Klotz DM, Walker MP, Diaugustine RP (2004) Mammary gland branching morphogenesis is diminished in mice with a deficiency of insulin-like growth factor-I (IGF-I), but not in mice with a liver-specific deletion of IGF-I. *Endocrinology* 145(7):3106–3110.
14. Bonnette SG, Hadsell DL (2001) Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. *Endocrinology* 142(11):4937–4945.
15. Pond AC, et al. (2013) Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function. *Stem Cells* 31(1):178–189.
16. Lu P, Ewald AJ, Martin GR, Werb Z (2008) Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. *Dev Biol* 321(1):77–87.
17. Peters G, Brookes S, Smith R, Dickson C (1983) Tumorigenesis by mouse mammary tumor virus: Evidence for a common region for provirus integration in mammary tumors. *Cell* 33(2):369–377.
18. Xian W, Schwertfeger KL, Rosen JM (2007) Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition. *Mol Endocrinol* 21(4):987–1000.
19. Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM (2005) Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. *J Cell Biol* 171(4):663–673.
20. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: Regulators of the tumor microenvironment. *Cell* 141(1):52–67.
21. Sternlicht MD, Kouros-Mehr H, Lu P, Werb Z (2006) Hormonal and local control of mammary branching morphogenesis. *Differentiation* 74(7):365–381.
22. Luetkeke NC, et al. (1999) Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. *Development* 126(12):2739–2750.
23. Ciarloni L, Mallepell S, Briskin C (2007) Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. *Proc Natl Acad Sci USA* 104(13):5455–5460.
24. Sternlicht MD, et al. (2005) Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. *Development* 132(17):3923–3933.
25. Stern DF (2000) Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. *Breast Cancer Res* 2(3):176–183.
26. Issa A, et al. (2013) Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. *Breast Cancer Res* 15(1):R8.
27. Basson MA, et al. (2005) Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. *Dev Cell* 8(2):229–239.
28. Klein OD, et al. (2008) An FGF signaling loop sustains the generation of differentiated progeny from stem cells in mouse incisors. *Development* 135(2):377–385.
29. Panagiotaki N, Dajas-Bailador F, Amaya E, Papalopulu N, Dorey K (2010) Characterisation of a new regulator of BDNF signalling, Sprouty3, involved in axonal morphogenesis in vivo. *Development* 137(23):4005–4015.
30. Zhang X, Qiao G, Lu P (2014) Modulation of fibroblast growth factor signaling is essential for mammary epithelial morphogenesis. *PLoS One* 9(4):e92735.
31. Thum T, et al. (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature* 456(7224):980–984.
32. Shim K, Minowada G, Coling DE, Martin GR (2005) Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. *Dev Cell* 8(4):553–564.
33. Ching ST, Cunha GR, Baskin LS, Basson MA, Klein OD (2014) Coordinated activity of Spry1 and Spry2 is required for normal development of the external genitalia. *Dev Biol* 386(1):1–11.
34. Shackleton M, et al. (2006) Generation of a functional mammary gland from a single stem cell. *Nature* 439(7072):84–88.
35. Shaw FL, et al. (2012) A detailed mammosphere assay protocol for the quantification of breast stem cell activity. *J Mammary Gland Biol Neoplasia* 17(2):111–117.
36. Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. *Nat Methods* 4(4):359–365.
37. Dikic I, Giordano S (2003) Negative receptor signalling. *Curr Opin Cell Biol* 15(2):128–135.
38. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA (1998) *sprouty* encodes a novel antagonist of FGF signaling that patterns apical branching of the *Drosophila* airways. *Cell* 92(2):253–263.
39. Arora S, et al. (2008) Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip. *Genome Biol* 9(11):R166.
40. Tarcic G, et al. (2012) EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. *FASEB J* 26(4):1582–1592.
41. Solca FF, et al. (2004) Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. *J Pharmacol Exp Ther* 311(2):502–509.
42. Zhang X, et al. (2014) FGF ligands of the postnatal mammary stroma regulate distinct aspects of epithelial morphogenesis. *Development* 141(17):3352–3362.
43. Mohammadi M, et al. (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. *Science* 276(5314):955–960.
44. Gaggioli C, et al. (2007) Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. *Nat Cell Biol* 9(12):1392–1400.
45. Casaleto JB, McClatchey AI (2012) Spatial regulation of receptor tyrosine kinases in development and cancer. *Nat Rev Cancer* 12(6):387–400.
46. Calmont A, et al. (2006) An FGF response pathway that mediates hepatic gene induction in embryonic endoderm cells. *Dev Cell* 11(3):339–348.
47. Bhowmick NA, et al. (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science* 303(5659):848–851.
48. Kajanne R, et al. (2007) EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. *J Cell Physiol* 212(2):489–497.
49. Wiseman BS, et al. (2003) Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. *J Cell Biol* 162(6):1123–1133.
50. Alcaraz J, et al. (2011) Collective epithelial cell invasion overcomes mechanical barriers of collagenous extracellular matrix by a narrow tube-like geometry and MMP14-dependent local softening. *Integr Biol (Camb)* 3(12):1153–1166.
51. Lu P, Takai K, Weaver VM, Werb Z (2011) Extracellular matrix degradation and remodeling in development and disease. *Cold Spring Harb Perspect Biol* 3(12):a005058.